Aicardi-Goutières syndrome (AGS) is a rare, genetically determined early-onset progressive encephalopathy. To date, mutations in six genes have been identified as etiologic for AGS. Our Japanese nationwide AGS survey identified six AGS-affected individuals without a molecular diagnosis; we performed whole-exome sequencing on three of these individuals. After removal of the common polymorphisms found in SNP databases, we were able to identify IFIH1 heterozygous missense mutations in all three. In vitro functional analysis revealed that IFIH1 mutations increased type I interferon production, and the transcription of interferon-stimulated genes were elevated. IFIH1 encodes MDA5, and mutant MDA5 lacked ligand-specific responsiveness, similarly to the dominant Ifih1 mutation responsible for the SLE mouse model that results in type I interferon overproduction. This study suggests that the IFIH1 mutations are responsible for the AGS phenotype due to an excessive production of type I interferon. We recently conducted a nationwide survey of AGS in Japan and reported 14 AGS-affected individuals. 10 We have since recruited three other Japanese AGS-affected individuals, and among these 17 individuals, we have identified 11 individuals with etiologic mutations; namely, TREX1 mutations in six, SAMHD1 mutations in three, and RNASEH2A and RNASEH2B mutations in one each.
Aicardi-Goutières syndrome (AGS [MIM 225750]) is a rare, genetically determined early-onset progressive encephalopathy. 1 Individuals affected with AGS typically suffer from progressive microcephaly associated with severe neurological symptoms, such as hypotonia, dystonia, seizures, spastic quadriplegia, and severe developmental delay. 2 On brain imaging, AGS is characterized by basal ganglia calcification, white matter abnormalities, and cerebral atrophy. 3, 4 Cerebrospinal fluid (CSF) analyses show chronic lymphocytosis and elevated levels of IFN-a and neopterin. [3] [4] [5] AGS-affected individuals are often misdiagnosed as having intrauterine infections, such as TORCH syndrome, because of the similarities of these disorders, particularly the intracranial calcifications. 1 In AGS, etiological mutations have been reported in the following six genes: TREX1 (MIM 606609), which encodes a DNA exonuclease; RNASEH2A (MIM 606034), RNASEH2B (MIM 610326), and RNASEH2C (MIM 610330), which together comprise the RNase H2 endonuclease complex; SAMHD1 (MIM 606754), which encodes a deoxynucleotide triphosphohydrolase; and ADAR1 (MIM 146920), which encodes an adenosine deaminase. [6] [7] [8] [9] Although more than 90% of AGS-affected individuals harbor etiological mutations in one of these six genes, some AGS-affected individuals presenting with the clinical characteristics of AGS still lack a genetic diagnosis, suggesting the existence of additional AGS-associated genes. 1 We recently conducted a nationwide survey of AGS in Japan and reported 14 AGS-affected individuals. 10 We have since recruited three other Japanese AGS-affected individuals, and among these 17 individuals, we have identified 11 individuals with etiologic mutations; namely, TREX1 mutations in six, SAMHD1 mutations in three, and RNASEH2A and RNASEH2B mutations in one each.
Of the remaining six individuals without a molecular diagnosis, trio-based whole-exome sequencing was performed in three whose parents also agreed to participate in further genome-wide analyses ( Figure 1A ). Genomic DNA from each individual and the parents was enriched for protein-coding sequences, followed by massively parallel sequencing. The extracted nonsynonymous or splice-site variants were filtered to remove those with minor allele frequencies (MAF) > 0.01 in dbSNP137. To detect de novo variants, any variants observed in family members, listed in Human Genetic Variation Database (HGVD), or with MAF > 0.02 in our in-house exome database were removed. To detect autosomal-recessive (AR), compound heterozygous (CH), or X-linked (XL) variants, those with MAF > 0.05 in our in-house database were removed (Figure S1 available online). All samples were collected with the written informed consents by parents, and the study protocol was approved by the ethical committee of Kyoto University Hospital in accordance with the Declaration of Helsinki. After common polymorphisms were removed, we identified a total of 40, 18, 89, and 22 candidate variants under the de novo, AR, CH, and XL inheritance models, respectively, that were present in at least one of the three individuals (Table S1 ). Among them, missense mutations were identified in IFIH1 (MIM 606951, RefSeq accession number NM_022168.2), which encodes MDA5 (RefSeq NP_071451.2). These missense mutations are c.1354G>A (p.Ala452Thr) in AGS-1; c.1114C>T (p.Leu372Phe) in AGS-2; and c.2336G>A (p.Arg779His) in AGS-3 ( Figure 1B) . None of the mutations are found in HGVD, including the 1,208 Japanese samples, or our in-house exome database of 312 Japanese individuals. Multiplesequence alignment by ClustalW2 revealed that each of the amino acids affected by these mutations are conserved among mammals ( Figure 1B) . The subsequent amino acid alterations were all suggested to be disease causing in at least one of the four function-prediction programs used ( Table  1 ). None of the other genes identified in the de novo inheritance model, or any of the genes identified in the other three inheritance models, were mutated in all three individuals. The IFIH1 mutations identified were validated by Sanger sequencing. The other coding exons of IFIH1 were also examined by Sanger sequencing, and no other mutations were found.
MDA5 is one of the cytosolic pattern recognition receptors that recognizes double-stranded RNA (dsRNA).
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MDA5 consists of N-terminal tandem CARD domains, a central helicase domain, and a C-terminal domain ( Figure 1C ). When bound to dsRNA, MDA5 forms a closed, C-shaped ring structure around the dsRNA stem and excludes the tandem CARD as well as creates filamentous oligomer on dsRNA. 12 It is hypothesized that the tandem CARD interacts each other and activates MAVS on the mitochondrial outer membrane. Oligomerization of MAVS induces TBK1 activation, IRF3 phosphorylation, and induction of type I interferon transcription, resulting in the activation of a large number of interferon-stimulated genes (ISGs). The neurological findings of the individuals with these IFIH1 mutations are typical of AGS (Table S2 ). They were born with appropriate weights for their gestational ages without any signs of intrauterine infection. However, they all demonstrated severe developmental delay in early infancy associated with progressive microcephaly. No arthropathy, hearing loss, or ophthalmological problems were observed. As for extraneural features, all three individuals had at least one of the following autoimmune features: positivity for autoantibodies, hyperimmunoglobulinemia, hypocomplementemia, and thrombocytopenia. Notably, none of the individuals with IFIH1 mutations had chilblain lesions, although all the five individuals with TREX1 mutations and two of the three individuals with SAMHD1 mutations in the Japanese AGS cohort showed chilblain lesions. 10 Individuals with SAMHD1 mutations and IFIH1 mutations both show autoimmune features; however, chilblain lesions have been observed only in individuals with SAMHD1 mutations.
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To predict the effects of the identified amino acid substitutions on MDA5, three-dimensional model structures of MDA5 mutants were generated from the crystal structure of human MDA5-dsRNA complex 12 (Protein Data Bank
[PDB] code 4gl2), using PyMOL (Schroedinger) and MOE (Chemical Computing Group) ( Figure S2A ). The oligomeric model of MDA5 was generated using the electron microscopy imaging data of MDA5 filament lacking CARD domain recent report showing that Lys777, close to Arg779, is in close proximity to the adjacent monomer. 12 Furthermore, in our model, Arg779 is in close to Asp572 on the surface of the adjacent monomer. We speculate that losing the positive charge due to the p.Arg779His substitution would possibly affect the electrostatic interaction between the MDA5 monomers ( Figures S2G and S2H ).
To connect the identified IFIH1 mutations with the AGS phenotype, we examined the type I interferon signature in the individuals by performing quantitative RT-PCR (qRT-PCR) of seven ISGs.
14 Peripheral blood mononuclear cells (PBMCs) from the three AGS-affected individuals showed upregulation of ISG transcription (Figure 2 ), confirming the type I interferon signature in the individuals with IFIH1 mutations.
To elucidate the disease-causing capability of the identified IFIH1 mutations, three FLAG-tagged IFIH1 mutant plasmids containing these mutations were constructed via site-directed mutagenesis. These plasmids were transiently expressed on human hepatoma cell line Huh7 and the IFNB1 promoter activity as well as endogenous expression of IFIT1 (MIM 147690) was measured 48 hr after transfection. 15 The three mutant plasmids activated the IFNB1 promoter in Huh7 cells more strongly than the wild MDA5 and nearby missense variants reported in dbSNP (Figures 3  and S3 ). The upregulation of endogenous IFIT1 was also observed in the transfected cells ( Figure S4 ), suggesting that these AGS mutations enhance the intrinsic activation function of MDA5. Recent genome-wide association studies (GWASs) showed association of the IFIH1 with various autoimmune diseases, such as systemic lupus erythematosus (SLE), type I diabetes, psoriasis, and vitiligo. [16] [17] [18] [19] We examined IFNB1 promoter activity induced by the c.2836G>A (p.Ala946Thr) polymorphism (rs1990760) identified in the GWASs. Although the c.2836G>A polymorphism partially activated the promoter activity, the induced activity was lower than those of the AGS-derived mutants. In addition, the dominantly inherited SLE mouse model in the ENUtreated mouse colony is reported to have the Ifih1 mutation, c.2461G>A (p.Gly821Ser). 15 These observations suggest that IFIH1 has strong association with various autoimmune diseases, especially SLE, which also has a type I interferon signature. 20 Because alteration of TREX1 has been reported to cause AGS as well as SLE, 21 it seems quite plausible for IFIH1 to also be involved in both AGS and SLE. Interestingly, all the individuals identified with IFIH1 mutations had autoantibodies, suggesting the contribution of IFIH1 mutations to autoimmune phenotypes.
To further delineate the functional consequences of the three IFH1 mutations, we measured the ligand-specific Ifnb mRNA induction by stimulating Ifih1 null mouse embryonic fibroblasts (MEFs) reconstituted with retrovirus expressing the IFIH1 mutants by an MDA5-specific ligand, encephalomyocarditis virus (EMCV). 22 None of the MEF cells expressing the three mutant IFIH1 responded to the EMCV, which suggested that the MDA5 variants lacked the ligand-specific responsiveness. The response of the three AGS mutants against the MDA5-specific EMCV was similar to that of the p.Gly821Ser variant reported in the dominantly inherited SLE mouse model with type I interferon overproduction 15 ( Figures 4 and S5 ).
During the revision of this manuscript, Rice et al. identified nine individuals with IFIH1 mutations, including the c.2336G>A mutation we identified, in a spectrum of neuroimmunological features consistently associated with enhanced type I interferon states including AGS. 23 Although we agree that the IFIH1 mutations cause constitutive type I interferon activation, Rice et al. show that the mutated MDA5 proteins maintain ligand-induced responsiveness, which was not the case in our study. Because we measured the ligand-specific responsiveness of MDA5 in different experimental conditions, further analysis remains to be performed to reveal the biochemical mechanism of interferon overproduction by the mutated MDA5. The potential functional effects of the IFIH1 variants identified in the AGS-affected individuals were predicted via SIFT, PolyPhen2, Mutation Taster, and PROVEAN.
Figure 2. Quantitative RT-PCR of a Panel of Seven ISGs in
PBMCs Obtained from the IFIH1-Mutated Individuals and Healthy Control Subject qRT-PCR was performed as previously described. 15 The relative abundance of each transcript was normalized to the expression level of b-actin. Taqman probes used were the same as previous report, 14 except for ACTB (MIM 102630). Individual data were shown relative to a single calibrator (control 1). The experiment was performed in triplicate. Statistical significance was determined by Mann-Whitney U test, *p < 0.05.
In conclusion, we identified mutations in IFIH1 as a cause of AGS. The individuals with the IFIH1 mutations showed encephalopathy typical of AGS as well as the type I interferon signature with autoimmune phenotypes, but lacked the chilblains. Further analysis remains to elucidate the mechanism of how the IFIH1 mutations identified in AGS cause the type I interferon overproduction. promoter (p-55C1B Luc), an empty vector (BOS), and expression vectors for FLAG-tagged human wild-type IFIH1, c.2836G>A polymorphism (p.Ala946Thr) in the GWASs, and the identified IFIH1 mutants. Luciferase activity was measured 48 hr after transfection, and the MDA5 protein accumulation was examined by immunoblotting as previously described. 15 FLAG indicates the accumulation of FLAG-tagged MDA5. Each experiment was performed in triplicate and data are mean 5 SEM. Shown is a representative of two with consistent results. Statistical significance was determined by Student's t test. *p < 0.05, **p < 0.01. IFNB1 promoter activity Ifih1 null MEFs were transfected with empty retrovirus vector, retrovirus encoding FLAGmouse wild type Ifih1 (WT) or FLAG-mouse Ifih1 with p.Gly821Ser mutation, or the FLAGtagged three AGS mutants of human IFIH1. The FLAG-tagged MDA5 and β-Actin accumulation was examined by Western blotting. The upper limit of normal CSF neopterin in our institute is 34.6nM at an age of 1-12 months and 25nM at an age of 2-12 years
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